Stocks
Taysha Gene Therapies, Inc.TSHA
NASDAQHealthcareBiotechnology$3.96
Price as of · delayed, not real-time
A clinical-stage biotechnology company focused on developing gene therapies for rare genetic diseases, with a pipeline targeting conditions such as Huntington's disease and Rett syndrome. Its lead programs are in early-stage trials, and the stock is closely watched by investors for clinical data readouts and partnership potential in the gene therapy space.
52W Range: $3.46-$7.30
Congressional Interest in Taysha Gene Therapies, Inc. (TSHA)
No congressional trades have been disclosed for Taysha Gene Therapies, Inc. (TSHA) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading TSHA?
No congressional trades found for this stock.